We have evaluated the prognostic significance of recurrent genomic aberrations including del(13q), t(11:14)/CyclinD1, t(4;14)/FGFR3, t(14;16)/c-Maf, del(17p)(p53), 1q21(CKS1B) amplification, 1p21/CDC14a deletion, and PTEN deletions, as well as CD56 expression in large cohorts of MM patients uniformly treated at our center [10-26]. This evidence concerns the gene TP53 and Miyoshi myopathy.